Show simple item record

dc.contributor.authorHosseini, M
dc.contributor.authorHaji-Fatahaliha, M
dc.contributor.authorMiahipour, A
dc.contributor.authorYousefi, M
dc.date.accessioned2018-08-26T04:56:35Z
dc.date.available2018-08-26T04:56:35Z
dc.date.issued2017
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/38518
dc.description.abstractLeishmaniasis is a major public infectious disease caused by the genus Leishmania. No effective drug or vaccination strategy for leishmaniasis has been designed yet. Several intracellular Leishmania antigens have been recognized to serve in vaccination, ensuring long-lasting protection against Leishmania infection. Lipophosphoglican 3 (LPG3) as a member of the heat shock protein 90 family involves in the synthesis of lipophosphoglycan (LPG) and implicates in parasite virulence. Regarding the immunological properties of LPG3 particularly its N-terminal fragment, it would be considered as a favourable adjuvant in Leishmania vaccination.
dc.language.isoEnglish
dc.relation.ispartofBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
dc.subjectAdaptive Immunity
dc.subjectAnimals
dc.subjectGlycosphingolipids
dc.subjectHeat-Shock Proteins
dc.subjectHumans
dc.subjectImmunity, Innate
dc.subjectLeishmania
dc.subjectVaccination
dc.titleNew insights to structure and immunological features of Leishmania lipophosphoglycan3.
dc.typearticle
dc.citation.volume95
dc.citation.spage1369
dc.citation.epage1374
dc.citation.indexPubmed
dc.identifier.DOIhttps://doi.org/10.1016/j.biopha.2017.09.061


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record